Patient preferences to value health outcomes in rheumatology clinical trials: Report from the OMERACT special interest group*

M. Thomas; L. Fraenkel; A. Boonen; N. Bansback; R. Buchbinder; D. Marshall; L. Proulx; M. Voshaar; P. Richards; D.P. Richards; M. Hiligsmann; F. Guillemin; B. Shea; P. Tugwell; G. Hazlewood

doi:10.1016/j.semarthrit.2021.05.008

Patient preferences to value health outcomes in rheumatology clinical trials: Report from the OMERACT special interest group*

M. Thomas, L. Fraenkel, A. Boonen, N. Bansback, R. Buchbinder, D. Marshall, L. Proulx, M. Voshaar, P. Richards, D.P. Richards, M. Hiligsmann, F. Guillemin, B. Shea, P. Tugwell, G. Hazlewood^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

2 Citations (Web of Science)

46 Downloads (Pure)

Abstract

Objective: To inform a research plan for future studies by obtaining stakeholder input on the application of preference-based methods to clinical trial design. Methods: We conducted a virtual OMERACT session to encourage stakeholder engagement. We developed materials for the session to facilitate discussion based on identified case examples and feedback sessions. Results: Participants prioritized incorporating patient preferences in all aspects of trial design with an empha-sis on outcome selection. Participants highlighted the need for careful consideration around preference het-erogeneity and equity factors. Conclusion: Including patient preferences in trial design was considered a priority requiring further explora-tion to develop comprehensive guidance. (c) 2021 Elsevier Inc. All rights reserved.

Original language	English
Pages (from-to)	919-924
Number of pages	6
Journal	Seminars in Arthritis and Rheumatism
Volume	51
Issue number	4
DOIs	https://doi.org/10.1016/j.semarthrit.2021.05.008
Publication status	Published - 1 Aug 2021

Keywords

OMERACT
Patient preferences
Preference-based methods
Rheumatology
Clinical trials
Trade-offs

Access to Document

10.1016/j.semarthrit.2021.05.008

Full TextFinal published version, 736 KBLicence: Taverne

Cite this

Thomas, M., Fraenkel, L., Boonen, A., Bansback, N., Buchbinder, R., Marshall, D., Proulx, L., Voshaar, M., Richards, P., Richards, D. P., Hiligsmann, M., Guillemin, F., Shea, B., Tugwell, P., & Hazlewood, G. (2021). Patient preferences to value health outcomes in rheumatology clinical trials: Report from the OMERACT special interest group*. Seminars in Arthritis and Rheumatism, 51(4), 919-924. https://doi.org/10.1016/j.semarthrit.2021.05.008

@article{a69b7f6a19f64a94b133655d7e62a65e,

title = "Patient preferences to value health outcomes in rheumatology clinical trials: Report from the OMERACT special interest group*",

abstract = "Objective: To inform a research plan for future studies by obtaining stakeholder input on the application of preference-based methods to clinical trial design. Methods: We conducted a virtual OMERACT session to encourage stakeholder engagement. We developed materials for the session to facilitate discussion based on identified case examples and feedback sessions. Results: Participants prioritized incorporating patient preferences in all aspects of trial design with an empha-sis on outcome selection. Participants highlighted the need for careful consideration around preference het-erogeneity and equity factors. Conclusion: Including patient preferences in trial design was considered a priority requiring further explora-tion to develop comprehensive guidance. (c) 2021 Elsevier Inc. All rights reserved.",

keywords = "OMERACT, Patient preferences, Preference-based methods, Rheumatology, Clinical trials, Trade-offs",

author = "M. Thomas and L. Fraenkel and A. Boonen and N. Bansback and R. Buchbinder and D. Marshall and L. Proulx and M. Voshaar and P. Richards and D.P. Richards and M. Hiligsmann and F. Guillemin and B. Shea and P. Tugwell and G. Hazlewood",

year = "2021",

month = aug,

day = "1",

doi = "10.1016/j.semarthrit.2021.05.008",

language = "English",

volume = "51",

pages = "919--924",

journal = "Seminars in Arthritis and Rheumatism",

issn = "0049-0172",

publisher = "W B Saunders Co-Elsevier Inc",

number = "4",

}

Thomas, M, Fraenkel, L, Boonen, A, Bansback, N, Buchbinder, R, Marshall, D, Proulx, L, Voshaar, M, Richards, P, Richards, DP, Hiligsmann, M, Guillemin, F, Shea, B, Tugwell, P & Hazlewood, G 2021, 'Patient preferences to value health outcomes in rheumatology clinical trials: Report from the OMERACT special interest group*', Seminars in Arthritis and Rheumatism, vol. 51, no. 4, pp. 919-924. https://doi.org/10.1016/j.semarthrit.2021.05.008

TY - JOUR

T1 - Patient preferences to value health outcomes in rheumatology clinical trials: Report from the OMERACT special interest group*

AU - Thomas, M.

AU - Fraenkel, L.

AU - Boonen, A.

AU - Bansback, N.

AU - Buchbinder, R.

AU - Marshall, D.

AU - Proulx, L.

AU - Voshaar, M.

AU - Richards, P.

AU - Richards, D.P.

AU - Hiligsmann, M.

AU - Guillemin, F.

AU - Shea, B.

AU - Tugwell, P.

AU - Hazlewood, G.

PY - 2021/8/1

Y1 - 2021/8/1

N2 - Objective: To inform a research plan for future studies by obtaining stakeholder input on the application of preference-based methods to clinical trial design. Methods: We conducted a virtual OMERACT session to encourage stakeholder engagement. We developed materials for the session to facilitate discussion based on identified case examples and feedback sessions. Results: Participants prioritized incorporating patient preferences in all aspects of trial design with an empha-sis on outcome selection. Participants highlighted the need for careful consideration around preference het-erogeneity and equity factors. Conclusion: Including patient preferences in trial design was considered a priority requiring further explora-tion to develop comprehensive guidance. (c) 2021 Elsevier Inc. All rights reserved.

AB - Objective: To inform a research plan for future studies by obtaining stakeholder input on the application of preference-based methods to clinical trial design. Methods: We conducted a virtual OMERACT session to encourage stakeholder engagement. We developed materials for the session to facilitate discussion based on identified case examples and feedback sessions. Results: Participants prioritized incorporating patient preferences in all aspects of trial design with an empha-sis on outcome selection. Participants highlighted the need for careful consideration around preference het-erogeneity and equity factors. Conclusion: Including patient preferences in trial design was considered a priority requiring further explora-tion to develop comprehensive guidance. (c) 2021 Elsevier Inc. All rights reserved.

KW - OMERACT

KW - Patient preferences

KW - Preference-based methods

KW - Rheumatology

KW - Clinical trials

KW - Trade-offs

U2 - 10.1016/j.semarthrit.2021.05.008

DO - 10.1016/j.semarthrit.2021.05.008

M3 - Article

C2 - 34134892

VL - 51

SP - 919

EP - 924

JO - Seminars in Arthritis and Rheumatism

JF - Seminars in Arthritis and Rheumatism

SN - 0049-0172

IS - 4

ER -